Loss expression of active fragile sites genes associated with the severity of breast epithelial abnormalities

Chinese Medical Journal

Volumn 121, Issue 20, 2008, Pages 1969-1974

  Wang, Tian Tian ^a   Frezza, Eldo E ^b   Ma, Rong ^a   Hu, San Yuan ^a   Liu, Chong Zhong ^a   Zhang, Guang Yong ^a   Wachtel, Mitchell S ^b   Lü, Xiao Mei ^c   Feng, Jin Bo ^d   Lü, Cui Xia ^e  

^a SHANDONG UNIVERSITY   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d Qilu Hospital of Shandong University   (China)

^e Shandong Center for Disease Control and Prevention   (China)

Author keywords

Breast neoplasms; Carcinogens; Chromosome fragile sites; Tumor suppressor genes

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE; ACID ANHYDRIDE HYDROLASE; OXIDOREDUCTASE; TUMOR PROTEIN; WWOX PROTEIN, HUMAN;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; BREAST HYPERPLASIA; BREAST SURGERY; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FROZEN SECTION; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BREAST; BREAST TUMOR; GENETICS; HYPERPLASIA; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; BREAST; BREAST NEOPLASMS; CHROMOSOME FRAGILE SITES; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; HYPERPLASIA; NEOPLASM PROTEINS; OXIDOREDUCTASES; TUMOR SUPPRESSOR PROTEINS;

EID: 58749085057     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200810020-00004     Document Type: Article

References (43)

1. Sipetić S, Petrović V, Milić Z, Vlajinac H. Breast cancer incidence among women of Branicevo region in the period 1991-2000. Med Pregl 2004; 57: 467-472.
2. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum androgeris, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005; 12: 1071-1082.
3. Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ. Aberrant p16 promoter hypermethylation in bronchial mucosae as a biomarker for the early detection of lung cancer. Chin Med J 2006; 119: 1469-1472.
4. Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, et al. Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 2006; 1089: 104-109.
5. Lixia M, Zhijian C, Chao S, Chaojiang G, Congyi Z. Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J Biochem Mol Biol 2007; 40: 15-21.
6. Lyman GH, Kuderer NM. Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. Clin Breast Cancer 2006; 7: 372-379.
7. Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol 2006; 16: 344-347.
8. Arlt MY, Casper AM, Glover TW. Common fragile sites Cytogenet Genome Res 2003; 100: 92-100.
9. Arlt MF, Miller DE, Beer DG, Glover TW. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer 2002; 33: 82-92.
10. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000; 60: 2140-2145.
11. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-597.
12. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999; 59: 3866-3869.
13. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032-5037.
14. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, et al. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 2000; 60: 1177-1182.
15. Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, et al. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 2000; 88: 24-34.
16. van Heerden WF, Swart TJ, van Heerden MB, van Rensburg EJ, Engelbrecht S, Dreyer L, et al. Immunohistochemical evaluation of Fhit protein expression in oral squamous cell carcinomas. J Oral Pathol Med 1999; 28: 433-437.
17. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001; 61: 4827-4836.
18. Cavazzoni A, Petronini PG, Galetti M, Roz L, Andriani F, Carbognani P, et al. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene 2004; 23: 8439-8446.
19. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A 2002; 99: 3615-3620.
20. Ishii H, Zanesi N, Vecchione A, Trapasso F, Yendamuri S. Sarti M, et al. Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J 2003; 17: 1768-1770.
21. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A 2001; 98: 11417-11422.
22. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001; 61: 8068-8073.
23. Mashimo T, Watabe M, Cuthbert AP, Newbold RF, Rinker-Schaeffer CW, Helfer E. et al. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res 1998; 58: 4572-4576.
24. Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori Y, Mori M, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 2002; 62: 2258-2260.
25. Yendamuri S, Kuroki T, Trapasso F, Henry AG, Dumon KR, Huebner K, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 2003; 63: 878-881.
26. Chang NS, Doherty J, Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 2003; 278: 9195-9202.
27. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618-1624.
28. Muti P. The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence. Ann N Y Acad Sci 2004; 1028: 273-282.
29. Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE, et al. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J 2005; 118: 1507-1516.
30. Zhang M, Yan JD, Zhang L, Wang Q, Lü SJ, Zhang J, et al. Activation of bone morphogenetic protein-6 gene transcription in MCF-7 cells by estrogen. Chin Med J 2005; 118: 1629-1636.
31. Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, et al. Adipocytokines and breast cancer risk. Chin Med J 2007; 120: 1592-1596.
32. Shaham J, Gurvich R, Goral A, Czerniak A. The risk of breast cancer in relation to health habits and occupational exposures. Am J Ind Med 2006; 49: 1021-1030.
33. Mukherjee S, Koner BC, Ray S, Ray A. Environmental contaminants in pathogenesis of breast cancer. Indian J Exp Biol 2006; 44: 597-617.
34. Sasco AJ. Breast cancer and the environment. Horm Res 2003; 60 Suppl 3: 50.
35. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist 2003; 8: 466-473.
36. Jakubowska A, Narod SA, Goldgar DE, Mierzejewski M, Masojd B, Nej K, et al. Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol Biomarkers Prev 2003; 12: 457-459.
37. Frank TS, Deffenbaugh AM, Hulick M, Gumpper K. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2. Dis Markers 1999; 15: 89-92.
38. Yakicier MC, Legoix P, Vaury C, Gressin L, Tubacher E, Capron F, et al. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 2001; 20: 5232-5238.
39. Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 2001; 159: 119-130.
40. Vecchione A, Zanesi N, Trombetta G, French D, Visca P, Pisani T, et al. Cervical dysplasia, ploidy, and human papillomavirus status correlate with loss of Fhit expression. Clin Cancer Res 2001; 7: 1306-1312.
41. Huiping C, Kristjansdottir S, Bergthorsson JT, Jonasson JG, Magnusson J, Egilsson V, et al. High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer 2002; 38: 728-735.
42. Huebner K, Croce CM. FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 2001; 1: 214-221.
43. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, et al. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 2005; 55: 471-478.